Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of GC2129A in Healthy Volunteers (Fed)
NCT05729386Phase 1Unknown
- Sponsor
- GC Biopharma Corp
- Start
- Feb 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GC2129A in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by GC Biopharma Corp. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to the last measurable concentration. Status: unknown.
02
Drugs
GC2129A
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05729386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05729386.